when will compounding pharmacies have to stop making tirzepatide FDA shut down compounded tirzepatide? Did the FDA Ban Compounded

Pratley RE, Nauck MA, Barnett AH, et al

Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School, said she doesnt support the use of compounded GLP-1 drugs but also worries that restrictions could add new strain to the overall supply

This includes insulin resistance, glucose intolerance, hepatic steatosis, very low adiponectin and leptin levels and hyperphagia, although not the hypertriglyceridemia observed in CGL2 patients

Thyroid-specific considerations: Although there is no established link between GLP-1 receptor agonists and Graves disease or hyperthyroidism, patients should be aware of thyroid-related warnings